Test drug SX-682 with decitabine for myelodysplastic syndrome
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 1 trial tests whether SX-682 given alone or with decitabine can treat myelodysplastic syndrome (MDS) that has not responded well to prior therapy. It also studies safety and the best dose, which may help people who have limited treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed MDS diagnosis based on standard criteria (WHO).
- Your MDS is in a specific risk group (low, intermediate-1, intermediate-2, or high risk) and matches their treatment history rules.
- If you already tried common MDS medicines (like azacitidine/decitabine, and sometimes lenalidomide), you either did not respond, stopped responding, or had to stop due to side effects or disease progression.
- You can do daily activities at a limited level or better (ECOG performance status 2 or less).
- Your blood/past sickness and organ labs must meet safety thresholds (kidney, liver, and bilirubin levels).
- You must be able to use study-approved birth control (and do a negative pregnancy test if applicable); do not breastfeed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This trial tests a new combination of two drugs—leflunomide and decitabine—for people with MDS that has come back or hasn't responded to treatment. The goal is to see if this combination can help control the disease.
This early-phase study tests whether combining two “epigenetic” medicines—azacitidine and decitabine—can improve outcomes for certain bone marrow cancers. It may help if you have a type of myelodysplastic syndrome (MDS) or MDS/MPN overlap that is expected to be sensitive to these medicines.
This Phase 1 trial studies how a pill form of decitabine/cedazuridine behaves in the body and how safe it is for people whose livers don’t work normally. It may help doctors better understand dosing and safety in patients with hepatic impairment.
This trial tests whether giving DEC-C (a decitabine-based treatment) soon after an allogeneic transplant can improve outcomes for MDS patients who still have “measurable residual disease” (hidden leftover disease) detectable by a genetic test. It also compares this approach to standard observation if the hidden disease is not detected or if the higher-risk safety checks are not met.
This Phase 1 trial studies how an oral combination cancer medicine behaves in the body (dose handling and safety) in people with kidney impairment. It may help doctors learn the safest way to use this treatment when kidney function is reduced.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.